NCT06681285View on ClinicalTrials.gov

Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Esophageal Carcinoma
Interventions
DRUG

Cadonilimab ;Anlotinib

Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Trial Locations (1)

050011

Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER

NCT06681285 - Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC) | Biotech Hunter | Biotech Hunter